- Edwards Lifesciences (EW +0.2%) upgraded to Overweight from Neutral with a $155 (18% upside) price target by JP Morgan.
- Anthera Pharmaceuticals (OTC:ANTH -2.2%) upgraded to Neutral from Sell by Citigroup.
- Aerie Pharmaceuticals (AERI) upgraded to Buy from Hold with a $15 (36% upside) price target by Cantor Fitzgerald.
- Cutera (CUTR +1.8%) upgraded to Overweight from Neutral with a $17 (21% upside) price target by Piper Jaffray.
- Cesca Therapeutics (KOOL -5.9%) downgraded to Neutral from Buy by H.C. Wainwright.
- Clovis Oncology (CLVS -7.1%) downgraded to Neutral from Overweight with $100 (6% upside) price target maintained by Piper Jaffray.
- Health Insurance Innovations (HIIQ +0.9%) downgraded to Neutral from Buy by Bank of America.
- Humana (HUM +0.1%) downgraded to Underperform from Neutral with a $150 (14% downside risk) price target by Sterne Agee CRT.
- Dyax (DYAX -0.2%) downgraded to Market Perform from Outperform by Oppenheimer.
- MannKind (MNKD +9.6%) downgraded to Underweight from Neutral by JP Morgan.
- Fluidigm (FLDM -2.2%) downgraded to Neutral from Buy with $30 (20% upside) price target by Mizuho Securities.